Literature DB >> 10705875

Lack of association between hyperprolactinemia and colon carcinoma.

H E Carlson1, M H Zarrabi, S L Lyubsky.   

Abstract

Two recent studies reported that many patients with colorectal carcinoma have elevated serum prolactin (PRL) concentrations and have suggested ectopic PRL secretion as the cause. In the present study, serum PRL was minimally elevated in 16 of 116 colon cancer patients and 2 of 25 control subjects; medications or chemotherapy appeared to be responsible for the PRL elevations in 11 of 16 cancer patients. Serum PRL was not correlated with either plasma carcinoembryonic antigen or disease stage. Preoperative and postoperative serum PRL concentrations were similar in 26 evaluated patients. None of 19 colorectal tumors was positive for PRL staining by immunohistochemistry. Thus, we could not confirm previous reports of frequent hyperprolactinemia in patients with colorectal cancer; factors such as medications, anxiety, pain, and nausea may have raised serum PRL in these earlier studies. Serum PRL is not a useful marker for colon carcinoma, at least in patients in the United States.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705875     DOI: 10.3109/07357900009038244

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Opposite association of serum prolactin and survival in patients with colon and rectal carcinomas: influence of preoperative radiotherapy.

Authors:  Marcos Gutiéerrez De La Barrera; Belem Trejo; Pedro Luna-Péerez; Fernándo López-Barrera; Gonzalo Martínez De La Escalera; Carmen Clapp
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.

Authors:  Atreyee Basu; Shashi Seth; Ashok K Chauhan; Nupur Bansal; Kanchan Arora; Anuradha Mahaur
Journal:  Ann Transl Med       Date:  2016-02

3.  Plasma prolactin in patients with colorectal cancer.

Authors:  Ahmad Reza Soroush; Hosein Mahmood Zadeh; Mehrnush Moemeni; Behnam Shakiba; Sara Elmi
Journal:  BMC Cancer       Date:  2004-12-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.